Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
152
resultados
Última actualización
25/04/2025 [06:56:00]
Resultados 100 a 125 de 152
Resumen de: EP4464242A2
The present disclosure provides apparatuses and methods for measuring capacitance as an indication of susceptibility to the formation of a diabetic foot ulcer.
Resumen de: US2019216405A1
The disclosure relates to a method and a system for determining a carbohydrate intake event from glucose monitoring data indicative of a glucose level in a system having a data processing device provided with one or more processors. The method comprises steps of: receiving a glucose monitoring value by the data processing device, the glucose monitoring value indicating a glucose level sampled from a person in a bodily fluid in a glucose level measurement; receiving, by the data processing device, insulin bolus administration data indicating an insulin bolus of an insulin bolus administration; determining, by the data processing device, from an analysis of the glucose monitoring value, a carbohydrate intake event if one of the following is detected: the glucose monitoring value indicates a glucose level below a first threshold glucose level; and the glucose monitoring value indicates an elevated glucose level above a second threshold glucose level, and the insulin bolus indicated by the insulin bolus administration data is exceeding a corrective insulin bolus suitable for compensating for the elevated glucose level; and generating, by the data processing device, carbohydrate intake event data indicating the determined carbohydrate intake event. Further, a non-transitory computer readable medium is provided.
Resumen de: US2019216405A1
The disclosure relates to a method and a system for determining a carbohydrate intake event from glucose monitoring data indicative of a glucose level in a system having a data processing device provided with one or more processors. The method comprises steps of: receiving a glucose monitoring value by the data processing device, the glucose monitoring value indicating a glucose level sampled from a person in a bodily fluid in a glucose level measurement; receiving, by the data processing device, insulin bolus administration data indicating an insulin bolus of an insulin bolus administration; determining, by the data processing device, from an analysis of the glucose monitoring value, a carbohydrate intake event if one of the following is detected: the glucose monitoring value indicates a glucose level below a first threshold glucose level; and the glucose monitoring value indicates an elevated glucose level above a second threshold glucose level, and the insulin bolus indicated by the insulin bolus administration data is exceeding a corrective insulin bolus suitable for compensating for the elevated glucose level; and generating, by the data processing device, carbohydrate intake event data indicating the determined carbohydrate intake event. Further, a non-transitory computer readable medium is provided.
Resumen de: WO2025054131A1
A blood glucose monitoring system having an insulin pump operational to administer insulin to the subject, sensors associated with the subject and operational to measure the blood glucose levels of a subject, and a computing device in electronic communication with the insulin pump. The computing device includes computer readable storage mediums having program code embodied therewith. The computing device includes a closed-loop insulin delivery algorithm trained to predict the blood glucose level of the subject. The algorithm includes a data-driven multi-step- ahead blood glucose predictor integrated with a linear time-varying model predictive control law. The computing device includes programming instructions for feeding the subject's blood glucose level into the algorithm, using the algorithm to predict if the blood glucose level of the subject is expected to reach a level representing hypoglycemia or hyperglycemia, and transmitting insulin administration instructions to the insulin pump based on the prediction.
Resumen de: AU2024213143A1
An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining an offset value for determining sensitivity; determining a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining sensitivity by adjusting the first sensitivity, wherein the determining of the sensitivity includes obtaining one sensitivity, and determining sensitivity A by adjusting the one sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the one sensitivity; and determining the sensitivity A as the sensitivity. Current Calibration point in time value S1:25 S1:5 Ss:20 Ss :20 ->S2 :20 ->S2 :20/3 P1 P2 Time Current ® Calibration point in time value 1 :29 81 :30 S1 32 Ss :25 Sp :25I Sp :27 ->S3 :27 P1 P2 P3 Time
Resumen de: US2025082840A1
A smart charging station may be capable of accessing data from an ambulatory medicament device at particular times, such as when the ambulatory medicament device is charging or connected to the charging station. The smart charging station may then communicate the data to another electronic system, such as a remote system. Advantageously, the charging station enables an ambulatory medicament device that may not be capable of communicating with a remote system to transfer ambulatory medicament device data to the remote system. Further, the remote system may communicate with the ambulatory medicament device via the charging station enabling, for example, control parameter updates, software updates, or permission modifications, among other communications with the ambulatory medicament device regardless of whether direct communication with the ambulatory medicament device is possible.
Resumen de: US2025087348A1
A method of treatment of a type 2 diabetic patient includes selecting a type 2 diabetic patient having a predetermined comorbidity for treatment, initiating a continuous glucose monitor regimen for the selected type 2 diabetic patient, wherein after six months of initiation of the continuous glucose monitor regimen, a rate of hospitalization for a predetermined diagnostic category of the selected patient having the predetermined comorbidity is reduced by at least 12% relative to an average rate of hospitalization for the predetermined diagnostic category of selected patients having the predetermined comorbidity without the continuous glucose monitor regimen.
Resumen de: US2025082849A1
In an aspect, an apparatus for generating a temporal element of a medication is presented. The apparatus includes a display device and a processor in electronic communication with the display device. The apparatus includes a memory communicatively connected to the processor. The memory includes instructions configuring the processor to generate a user interface through the display device and receive user input from a user through the user interface. The processor is configured to receive biological data from a user through a biological sensor in communication with the processor. The biological data includes a gastric metric. The processor is configured to calculate a temporal element of a delivery of an amount of medication to the user based on the biological data and the user input. The processor is configured to communicate the temporal element of the delivery of the amount of medication to a wearable medication delivery device.
Resumen de: US2025085219A1
A process and sensor system with particular control of polarization of the interrogating light beams useful for determining a concentration of a targeted molecule M (such as glucose) within a given time period in a liquid sampling matrix through use of a Direct Infrared Laser Absorption Spectroscopy Technique.
Resumen de: US2025087350A1
Provided are computer-implemented methods, systems and devices for generating a type-II (T2DM) diabetic status prediction, including: extracting voice biomarker feature values from the voice sample for predetermined voice biomarker features; determining the T2DM diabetic status prediction for the subject based on the biomarker feature values and the diabetic status prediction model; and outputting the T2DM diabetic status prediction for the subject.Provided are computer-implemented methods, systems and devices for generating a diabetic status model for predicting a T2DM diabetic status, including: diabetic status labels identifying a corresponding diabetic status for training subjects; and voice samples collected from the training subjects at different time points, each of the voice samples associated with a corresponding diabetic status label; determining voice feature values for corresponding voice features for each of the voice samples in the voice samples; and generating the diabetic status model based on the voice samples and the voice feature values.
Resumen de: US2025082850A1
The exemplary embodiments may provide a secure framework for devices in a drug delivery system to wirelessly communicate. The secure framework may use encrypted keys to carry credentials and to specify the rights of the devices presenting the credentials. The devices in the drug delivery system present the keys at the time that they wish to wirelessly communicate with other devices in the drug delivery system. The devices receiving such keys, decrypt the keys and verify if the credentials are valid. If the credentials are valid, a wireless communication session between devices may be established.
Resumen de: UA129312C2
Described herein are fixed doses and dosing regimens for long-acting insulin receptor agonists suitable for once-weekly dosing, such as weekly basal insulin-Fc (BIF).
Resumen de: EP4520266A2
The present disclosure relates to a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device: includes a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use thereof, without additional work for connecting a separate transmitter, and easier maintenance; and is activated by a user's operation after the body attachment unit is attached to the body, so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Resumen de: US2022151520A1
A measuring device for determining an estimated value for the blood sugar content of a person using a non-invasive impedance measurement is provided. The measuring device includes a measurement transducer for determining a blood sugar content from a measured value and a sensor unit for detecting the measured value. The sensor unit has at least two tetrapolar electrode assemblies, which each have at least two electrode pairs arranged along a first linear axis. The axes of the two tetrapolar electrode assemblies are aligned perpendicularly to one another. A first electrode pair is provided for transmitting and receiving a current signal, and a second electrode pair is provided for tapping a potential on contact with the skin of the person. At least one of the electrodes of the sensor unit has a contact surface for contacting the skin, which contact surface consists of a metal or a metal alloy having a conductivity of more than 1*107 S/m.
Resumen de: MX378797B
The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.
Resumen de: WO2025048045A1
The present invention relates to a sensor strip storage-type device for measuring urine glucose levels and vascular elasticity, wherein the sensor strip storage-type device is capable of measuring urine glucose levels in a non-invasive manner, quantitatively measuring glucose levels through a digitized sensor, being capable of being conveniently carried by means of sealing and storing a plurality of sensor strips that can be used multiple times, and measuring vascular elasticity during use.
Resumen de: WO2025046158A1
The invention relates to a method for controlling glucose in a flexible-structure bihormonal artificial pancreas that manages optional meal and/or exercise alerts by means of coordinated control actions, comprising: measuring a plasma glucose signal; calculating an incremental plasma glucose measurement (y); defining a model for incremental plasma glucose; defining a carbohydrate ingestion as dependent on a carbohydrate content estimated by the patient; defining an expected postprandial incremental plasma glucose y*(s) according to an insulin bolus that has been administered; defining a corrected incremental plasma glucose y̅(s), a corrected insulin infusion ū(s) and a corrected carbohydrate ingestion d̅(s); defining a virtual control action μ(s), divided between regulatory actions μ r and counterregulatory actions μ cr ; and calculating the control actions using a 2-DOF feedback controller with a prefilter having a nominal value F r (s).
Resumen de: WO2025044331A1
Disclosed in the present invention is a closed-loop artificial pancreas system for safe infusion. During long-time missing of real-time blood glucose value data, on the basis of historical blood glucose values and blood glucose values of fingertips, the closed-loop artificial pancreas system can continue to calculate the infusion amount of insulin required by a patient and infuse a proper amount of insulin into the patient, and will not infuse an improper amount of insulin due to missing of real-time blood glucose value data and even interrupt the infusion of insulin, avoiding the life risk of the patient, and facilitating treatment of the patient.
Resumen de: AU2025201073A1
This document discusses, among other things, systems and methods to compensate for the effects of temperature on sensors, such as analyte sensor. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.
Resumen de: AU2023333103A1
Exemplary embodiments may apply a transform or filter to analyte level values of the users to make the analyte level values conform with a normal distribution that is symmetric relative to the mean. The transformed or filtered analyte level values may be used by the control system of a medicament delivery device in determining medicament delivery doses. In some embodiments, the medicament is insulin, and the analyte level is a glucose level of a user. In such instances, a logarithmic filter or transform may be applied to the glucose level readings of the user.
Resumen de: WO2025050007A1
The present disclosure describes lactate-responsive sensors, sensing systems incorporating a lactate-responsive sensor, and methods of use thereof that would be beneficial for continuously monitoring lactate levels and determining lactate thresholds (both aerobic and anaerobic thresholds). The present disclosure also relates to an analyte sensor for continuously detecting glucose and lactate levels.
Resumen de: US2025073440A1
A transport element for transporting a substance in a reservoir includes a transport means, such as a conduit, tube, hose or the like, and a connector arranged at an inlet end of the transport means for connecting to the reservoir such that in a connected condition in which the connector is connected to said reservoir a medium through flow connection is provided between said reservoir and the inlet end of the transport means for receiving said substance from said reservoir. The connector includes aligning and holding means for aligning and holding the reservoir in a predetermined orientation with respect to and/or position along a longitudinal axis of the connector. An infusion set, system or combination including transport element, and a method of at least fluidly connecting such a transport element to a reservoir.
Resumen de: US2025072792A1
The present invention discloses a system and method for managing blood glucose level. The system comprises a computing device in communication with a continuous glucose monitoring (CGM) device attached to a user and a wearable device configured to be worn by the user. The computing device is configured to receive the blood glucose level of the user from the continuous glucose monitoring device, or its associated app. The computing device is further configured to enable the user to set one or more predetermined ranges of blood glucose level and set an alert for each predefined range. The computing device is further configured to determine whether the blood glucose level is within one or more predetermined ranges. The computing device is further configured to determine at least one alert corresponding to the blood glucose level and enable the wearable device to provide the determined alert until the user disables the alert.
Resumen de: US2025072774A1
The present disclosure relates to noninvasive methods, devices, and systems for measuring various blood constituents or analytes, such as glucose. In an embodiment, a light source comprises LEDs and super-luminescent LEDs. The light source emits light at at least wavelengths of about 1610 nm, about 1640 nm, and about 1665 nm. In an embodiment, the detector comprises a plurality of photodetectors arranged in a special geometry comprising one of a substantially linear substantially equal spaced geometry, a substantially linear substantially non-equal spaced geometry, and a substantially grid geometry.
Nº publicación: US2025072793A1 06/03/2025
Solicitante:
UNIV OF VIRGINIA PATENT FOUNDATION [US]
UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Resumen de: US2025072793A1
Embodiments relate to a system for processing glucose data by efficient glucose database management. The system includes a physical data store containing glucose measurement data and a representation for at least one cluster of the glucose measurement data, wherein the representation approximates a glycemic profile vector array for a cluster of multiple glucose profiles segmented by plural time ranges. The system includes a processor and computer memory configured with instructions stored thereon that when executed will cause the processor to: 1) receive glucose measurements; 2) convert the glucose measurements into vectorial form; 3) search the physical data store by comparing a newly received glucose measurement to a centroid of a cluster using a similarity metric; 3) classify the newly received glucose measurement with a cluster having a matched similarity metric based on the comparing; and 4) ascribe a treatment to the newly received glucose measurement.
BOPI
Sede Electrónica
